Merck & Co Inc

NYSE:MRK  
76.85
-0.08 (-0.10%)
4:43:40 PM EDT: $77.02 +0.17 (+0.22%)
Products

FDA Approves Expanded Indication For Merck’S Keytruda® (Pembrolizumab) In Locally Advanced Cutaneous Squamous Cell Carcinoma (Cscc)

Published: 07/06/2021 10:56 GMT
Merck & Co Inc (MRK) - FDA Approves Expanded Indication for Merck’s Keytruda® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cscc).
Merck - Keytruda Now Approved for Treatment of Patients With Recurrent Or Metastatic Or Locally Advanced Cscc That is Not Curable by Surgery Or Radiation.